PLEASE READ CAREFULLY BEFORE STARTING THE ONLINE ABSTRACT SUBMISSION PROCESS
Submission: All abstracts must be submitted using the AOS online abstract form.
Abstract: The abstract of 300 words or less must be structured in the following format:
Required fields for Continuing Medical Education (CME):
The following information will be used by the Committee on Programs to evaluate submitted abstracts. This information will not appear in the final, printed abstract, but is crucial to the review process. In order to be considered for a paper presentation, you must satisfactorily complete the CME question requirements.
Off-Label Use: Discussion of an off-label use of a commercial product and/or discussion of an investigational drug or device must be disclosed in the abstract form.
IRB Documentation Status: The author must indicate the Institutional Review Board (IRB) status of the study. Studies involving human subjects require IRB approval. Experimental investigations involving animals must conform to the generally accepted principles of animal maintenance and care or adhere to ARVO principles for use of animals in ophthalmic or vision research.
Financial Disclosure: Before an abstract can be considered by the Committee on Programs, the presenting author must complete the separate Financial Disclosure form and list ONLY financial relationships that are RELEVANT to your participation in the AOS program. Individuals who have nothing to disclose must so declare. Unlike previous years, co-authors are not required to submit a financial disclosure.
A financial disclosure form is available on the AOS website.
If a RELEVANT financial disclosure is identified, a conflict of interest resolution process will be performed before your abstract will be considered for presentation.
Note: If your abstract is chosen for paper presentation, the presenting authors’ financial conflicts of interest, or lack thereof, must be noted on the first slide of the presentation. In addition, please:
Discussants: To assist the Discussant of the paper, the author must submit a list of talking points and the abstract to the assigned primary discussant at least six (6) weeks in advance of the meeting. The Discussant should also be provided with the slide presentation whenever possible. If modifications are made to the slides, the presentation must be resubmitted to the Discussant prior to the meeting.
Authors are required to suggest a minimum of three (3) members as possible Discussants. You may view the online member list by clicking here. Selection of the Discussants will be completed by March.
Publication: All abstracts – both paper and poster – will be published with free, open access in The Transactions on the AOS website, as well as at PubMedCentral.
You will receive notice of acceptance or rejection of your abstract for presentation in February.